1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Choroidal Neovascularization Drug Revenue
1.4 Market Analysis by Type
1.4.1 Global Choroidal Neovascularization Drug Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 AVMOC-001
1.4.3 BB-3
1.4.4 BBT-007
1.4.5 DG-3
1.4.6 Entolimod
1.4.7 EWA-001
1.4.8 Others
1.5 Market by Application
1.5.1 Global Choroidal Neovascularization Drug Market Share by Application: 2021-2026
1.5.2 Clinic
1.5.3 Hospital
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
1.8 Overview of Global Choroidal Neovascularization Drug Market
1.8.1 Global Choroidal Neovascularization Drug Market Status and Outlook (2015-2026)
1.8.2 North America
1.8.3 East Asia
1.8.4 Europe
1.8.5 South Asia
1.8.6 Southeast Asia
1.8.7 Middle East
1.8.8 Africa
1.8.9 Oceania
1.8.10 South America
1.8.11 Rest of the World
2 Market Competition by Manufacturers
2.1 Global Choroidal Neovascularization Drug Production Capacity Market Share by Manufacturers (2015-2020)
2.2 Global Choroidal Neovascularization Drug Revenue Market Share by Manufacturers (2015-2020)
2.3 Global Choroidal Neovascularization Drug Average Price by Manufacturers (2015-2020)
2.4 Manufacturers Choroidal Neovascularization Drug Production Sites, Area Served, Product Type
3 Sales by Region
3.1 Global Choroidal Neovascularization Drug Sales Volume Market Share by Region (2015-2020)
3.2 Global Choroidal Neovascularization Drug Sales Revenue Market Share by Region (2015-2020)
3.3 North America Choroidal Neovascularization Drug Sales Volume
3.3.1 North America Choroidal Neovascularization Drug Sales Volume Growth Rate (2015-2020)
3.3.2 North America Choroidal Neovascularization Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.4 East Asia Choroidal Neovascularization Drug Sales Volume
3.4.1 East Asia Choroidal Neovascularization Drug Sales Volume Growth Rate (2015-2020)
3.4.2 East Asia Choroidal Neovascularization Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.5 Europe Choroidal Neovascularization Drug Sales Volume (2015-2020)
3.5.1 Europe Choroidal Neovascularization Drug Sales Volume Growth Rate (2015-2020)
3.5.2 Europe Choroidal Neovascularization Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.6 South Asia Choroidal Neovascularization Drug Sales Volume (2015-2020)
3.6.1 South Asia Choroidal Neovascularization Drug Sales Volume Growth Rate (2015-2020)
3.6.2 South Asia Choroidal Neovascularization Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.7 Southeast Asia Choroidal Neovascularization Drug Sales Volume (2015-2020)
3.7.1 Southeast Asia Choroidal Neovascularization Drug Sales Volume Growth Rate (2015-2020)
3.7.2 Southeast Asia Choroidal Neovascularization Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.8 Middle East Choroidal Neovascularization Drug Sales Volume (2015-2020)
3.8.1 Middle East Choroidal Neovascularization Drug Sales Volume Growth Rate (2015-2020)
3.8.2 Middle East Choroidal Neovascularization Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.9 Africa Choroidal Neovascularization Drug Sales Volume (2015-2020)
3.9.1 Africa Choroidal Neovascularization Drug Sales Volume Growth Rate (2015-2020)
3.9.2 Africa Choroidal Neovascularization Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.10 Oceania Choroidal Neovascularization Drug Sales Volume (2015-2020)
3.10.1 Oceania Choroidal Neovascularization Drug Sales Volume Growth Rate (2015-2020)
3.10.2 Oceania Choroidal Neovascularization Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.11 South America Choroidal Neovascularization Drug Sales Volume (2015-2020)
3.11.1 South America Choroidal Neovascularization Drug Sales Volume Growth Rate (2015-2020)
3.11.2 South America Choroidal Neovascularization Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.12 Rest of the World Choroidal Neovascularization Drug Sales Volume (2015-2020)
3.12.1 Rest of the World Choroidal Neovascularization Drug Sales Volume Growth Rate (2015-2020)
3.12.2 Rest of the World Choroidal Neovascularization Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
4 North America
4.1 North America Choroidal Neovascularization Drug Consumption by Countries
4.2 United States
4.3 Canada
4.4 Mexico
5 East Asia
5.1 East Asia Choroidal Neovascularization Drug Consumption by Countries
5.2 China
5.3 Japan
5.4 South Korea
6 Europe
6.1 Europe Choroidal Neovascularization Drug Consumption by Countries
6.2 Germany
6.3 United Kingdom
6.4 France
6.5 Italy
6.6 Russia
6.7 Spain
6.8 Netherlands
6.9 Switzerland
6.10 Poland
7 South Asia
7.1 South Asia Choroidal Neovascularization Drug Consumption by Countries
7.2 India
7.3 Pakistan
7.4 Bangladesh
8 Southeast Asia
8.1 Southeast Asia Choroidal Neovascularization Drug Consumption by Countries
8.2 Indonesia
8.3 Thailand
8.4 Singapore
8.5 Malaysia
8.6 Philippines
8.7 Vietnam
8.8 Myanmar
9 Middle East
9.1 Middle East Choroidal Neovascularization Drug Consumption by Countries
9.2 Turkey
9.3 Saudi Arabia
9.4 Iran
9.5 United Arab Emirates
9.6 Israel
9.7 Iraq
9.8 Qatar
9.9 Kuwait
9.10 Oman
10 Africa
10.1 Africa Choroidal Neovascularization Drug Consumption by Countries
10.2 Nigeria
10.3 South Africa
10.4 Egypt
10.5 Algeria
10.6 Morocco
11 Oceania
11.1 Oceania Choroidal Neovascularization Drug Consumption by Countries
11.2 Australia
11.3 New Zealand
12 South America
12.1 South America Choroidal Neovascularization Drug Consumption by Countries
12.2 Brazil
12.3 Argentina
12.4 Columbia
12.5 Chile
12.6 Venezuela
12.7 Peru
12.8 Puerto Rico
12.9 Ecuador
13 Rest of the World
13.1 Rest of the World Choroidal Neovascularization Drug Consumption by Countries
13.2 Kazakhstan
14 Sales Volume, Sales Revenue, Sales Price Trend by Type
14.1 Global Choroidal Neovascularization Drug Sales Volume Market Share by Type (2015-2020)
14.2 Global Choroidal Neovascularization Drug Sales Revenue Market Share by Type (2015-2020)
14.3 Global Choroidal Neovascularization Drug Sales Price by Type (2015-2020)
15 Consumption Analysis by Application
15.1 Global Choroidal Neovascularization Drug Consumption Volume by Application (2015-2020)
15.2 Global Choroidal Neovascularization Drug Consumption Value by Application (2015-2020)
16 Company Profiles and Key Figures in Choroidal Neovascularization Drug Business
16.1 Cellphire, Inc.
16.1.1 Cellphire, Inc. Company Profile
16.1.2 Cellphire, Inc. Choroidal Neovascularization Drug Product Specification
16.1.3 Cellphire, Inc. Choroidal Neovascularization Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.2 Humanetics Corporation
16.2.1 Humanetics Corporation Company Profile
16.2.2 Humanetics Corporation Choroidal Neovascularization Drug Product Specification
16.2.3 Humanetics Corporation Choroidal Neovascularization Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.3 Cumberland Pharmaceuticals, Inc.
16.3.1 Cumberland Pharmaceuticals, Inc. Company Profile
16.3.2 Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Product Specification
16.3.3 Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.4 Chrysalis BioTherapeutics, Inc.
16.4.1 Chrysalis BioTherapeutics, Inc. Company Profile
16.4.2 Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Product Specification
16.4.3 Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.5 GNI Group Ltd.
16.5.1 GNI Group Ltd. Company Profile
16.5.2 GNI Group Ltd. Choroidal Neovascularization Drug Product Specification
16.5.3 GNI Group Ltd. Choroidal Neovascularization Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.6 Cleveland BioLabs, Inc.
16.6.1 Cleveland BioLabs, Inc. Company Profile
16.6.2 Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Product Specification
16.6.3 Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.7 Meabco A/S
16.7.1 Meabco A/S Company Profile
16.7.2 Meabco A/S Choroidal Neovascularization Drug Product Specification
16.7.3 Meabco A/S Choroidal Neovascularization Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.8 Eli Lilly and Company
16.8.1 Eli Lilly and Company Company Profile
16.8.2 Eli Lilly and Company Choroidal Neovascularization Drug Product Specification
16.8.3 Eli Lilly and Company Choroidal Neovascularization Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.9 Diffusion Pharmaceuticals Inc.
16.9.1 Diffusion Pharmaceuticals Inc. Company Profile
16.9.2 Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Product Specification
16.9.3 Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.10 INSYS Therapeutics, Inc.
16.10.1 INSYS Therapeutics, Inc. Company Profile
16.10.2 INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Product Specification
16.10.3 INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.11 ProCertus BioPharm Inc.
16.11.1 ProCertus BioPharm Inc. Company Profile
16.11.2 ProCertus BioPharm Inc. Choroidal Neovascularization Drug Product Specification
16.11.3 ProCertus BioPharm Inc. Choroidal Neovascularization Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.12 RxBio, Inc.
16.12.1 RxBio, Inc. Company Profile
16.12.2 RxBio, Inc. Choroidal Neovascularization Drug Product Specification
16.12.3 RxBio, Inc. Choroidal Neovascularization Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.13 Neumedicines Inc.
16.13.1 Neumedicines Inc. Company Profile
16.13.2 Neumedicines Inc. Choroidal Neovascularization Drug Product Specification
16.13.3 Neumedicines Inc. Choroidal Neovascularization Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.14 RDD Pharma Ltd.
16.14.1 RDD Pharma Ltd. Company Profile
16.14.2 RDD Pharma Ltd. Choroidal Neovascularization Drug Product Specification
16.14.3 RDD Pharma Ltd. Choroidal Neovascularization Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.15 Pluristem Therapeutics Inc.
16.15.1 Pluristem Therapeutics Inc. Company Profile
16.15.2 Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Product Specification
16.15.3 Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.16 Onconova Therapeutics, Inc.
16.16.1 Onconova Therapeutics, Inc. Company Profile
16.16.2 Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Product Specification
16.16.3 Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.17 Soligenix, Inc.
16.17.1 Soligenix, Inc. Company Profile
16.17.2 Soligenix, Inc. Choroidal Neovascularization Drug Product Specification
16.17.3 Soligenix, Inc. Choroidal Neovascularization Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.18 RedHill Biopharma Ltd.
16.18.1 RedHill Biopharma Ltd. Company Profile
16.18.2 RedHill Biopharma Ltd. Choroidal Neovascularization Drug Product Specification
16.18.3 RedHill Biopharma Ltd. Choroidal Neovascularization Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.19 PharmaIN Corporation
16.19.1 PharmaIN Corporation Company Profile
16.19.2 PharmaIN Corporation Choroidal Neovascularization Drug Product Specification
16.19.3 PharmaIN Corporation Choroidal Neovascularization Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
17 Choroidal Neovascularization Drug Manufacturing Cost Analysis
17.1 Choroidal Neovascularization Drug Key Raw Materials Analysis
17.1.1 Key Raw Materials
17.2 Proportion of Manufacturing Cost Structure
17.3 Manufacturing Process Analysis of Choroidal Neovascularization Drug
17.4 Choroidal Neovascularization Drug Industrial Chain Analysis
18 Marketing Channel, Distributors and Customers
18.1 Marketing Channel
18.2 Choroidal Neovascularization Drug Distributors List
18.3 Choroidal Neovascularization Drug Customers
19 Market Dynamics
19.1 Market Trends
19.2 Opportunities and Drivers
19.3 Challenges
19.4 Porter's Five Forces Analysis
20 Production and Supply Forecast
20.1 Global Forecasted Production of Choroidal Neovascularization Drug (2021-2026)
20.2 Global Forecasted Revenue of Choroidal Neovascularization Drug (2021-2026)
20.3 Global Forecasted Price of Choroidal Neovascularization Drug (2015-2026)
20.4 Global Forecasted Production of Choroidal Neovascularization Drug by Region (2021-2026)
20.4.1 North America Choroidal Neovascularization Drug Production, Revenue Forecast (2021-2026)
20.4.2 East Asia Choroidal Neovascularization Drug Production, Revenue Forecast (2021-2026)
20.4.3 Europe Choroidal Neovascularization Drug Production, Revenue Forecast (2021-2026)
20.4.4 South Asia Choroidal Neovascularization Drug Production, Revenue Forecast (2021-2026)
20.4.5 Southeast Asia Choroidal Neovascularization Drug Production, Revenue Forecast (2021-2026)
20.4.6 Middle East Choroidal Neovascularization Drug Production, Revenue Forecast (2021-2026)
20.4.7 Africa Choroidal Neovascularization Drug Production, Revenue Forecast (2021-2026)
20.4.8 Oceania Choroidal Neovascularization Drug Production, Revenue Forecast (2021-2026)
20.4.9 South America Choroidal Neovascularization Drug Production, Revenue Forecast (2021-2026)
20.4.10 Rest of the World Choroidal Neovascularization Drug Production, Revenue Forecast (2021-2026)
20.5 Forecast by Type and by Application (2021-2026)
20.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2021-2026)
20.5.2 Global Forecasted Consumption of Choroidal Neovascularization Drug by Application (2021-2026)
21 Consumption and Demand Forecast
21.1 North America Forecasted Consumption of Choroidal Neovascularization Drug by Country
21.2 East Asia Market Forecasted Consumption of Choroidal Neovascularization Drug by Country
21.3 Europe Market Forecasted Consumption of Choroidal Neovascularization Drug by Countriy
21.4 South Asia Forecasted Consumption of Choroidal Neovascularization Drug by Country
21.5 Southeast Asia Forecasted Consumption of Choroidal Neovascularization Drug by Country
21.6 Middle East Forecasted Consumption of Choroidal Neovascularization Drug by Country
21.7 Africa Forecasted Consumption of Choroidal Neovascularization Drug by Country
21.8 Oceania Forecasted Consumption of Choroidal Neovascularization Drug by Country
21.9 South America Forecasted Consumption of Choroidal Neovascularization Drug by Country
21.10 Rest of the world Forecasted Consumption of Choroidal Neovascularization Drug by Country
22 Research Findings and Conclusion
23 Methodology and Data Source
23.1 Methodology/Research Approach
23.1.1 Research Programs/Design
23.1.2 Market Size Estimation
23.1.3 Market Breakdown and Data Triangulation
23.2 Data Source
23.2.1 Secondary Sources
23.2.2 Primary Sources
23.3 Disclaimer